Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV.

IJTLD open Pub Date : 2024-09-01 DOI:10.5588/ijtldopen.23.0609

R Borse, B Randive, S Mattoo, P Malik, H Solanki, A Gupta, R E Chaisson, V Mave, N Suryavanshi

{"title":"Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV.","authors":"R Borse, B Randive, S Mattoo, P Malik, H Solanki, A Gupta, R E Chaisson, V Mave, N Suryavanshi","doi":"10.5588/ijtldopen.23.0609","DOIUrl":null,"url":null,"abstract":"Background: Evidence on implementation of three months of weekly isoniazid (H, INH) and rifapentine (P, RPT) (3HP) as a TB preventive therapy (TPT) for at-risk groups in Indian programmatic conditions is limited.Methods: A prospective demonstration study assessing scale-up, safety, and effectiveness of 3HP TPT among people living with HIV (PLHIV) in Indian programmatic settings was conducted.Results: Of 656 screened PLHIV, 502 (77%) received 3HP. Of these, 20 (4%) discontinued TPT due to toxicity,17 (3.8%) lost to follow-up, one (0.2%) had breakthrough rifampicin-sensitive TB, and 464 (92%) completed 3 HP TPT. Of 288 (57%) overall adverse events (AEs), 46 (9%) had Grade 2 or above AEs. The median time to AE was 14 days (IQR 7-42). Serious adverse events (SAEs) were reported in 9 (2%) participants; of these, 7 (78%) were not related to 3HP. No TB episodes occurred during the 1-year follow-up period.Conclusion: 3HP TPT completion rate of 92%, with few adverse events leading to 3HP discontinuation, providing evidence of the scalability and safety of 3HP TPT among PLHIV in Indian health program settings.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 9","pages":"404-409"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409171/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJTLD open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/ijtldopen.23.0609","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Evidence on implementation of three months of weekly isoniazid (H, INH) and rifapentine (P, RPT) (3HP) as a TB preventive therapy (TPT) for at-risk groups in Indian programmatic conditions is limited.

Methods: A prospective demonstration study assessing scale-up, safety, and effectiveness of 3HP TPT among people living with HIV (PLHIV) in Indian programmatic settings was conducted.

Results: Of 656 screened PLHIV, 502 (77%) received 3HP. Of these, 20 (4%) discontinued TPT due to toxicity,17 (3.8%) lost to follow-up, one (0.2%) had breakthrough rifampicin-sensitive TB, and 464 (92%) completed 3 HP TPT. Of 288 (57%) overall adverse events (AEs), 46 (9%) had Grade 2 or above AEs. The median time to AE was 14 days (IQR 7-42). Serious adverse events (SAEs) were reported in 9 (2%) participants; of these, 7 (78%) were not related to 3HP. No TB episodes occurred during the 1-year follow-up period.

Conclusion: 3HP TPT completion rate of 92%, with few adverse events leading to 3HP discontinuation, providing evidence of the scalability and safety of 3HP TPT among PLHIV in Indian health program settings.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

为预防艾滋病病毒感染者感染结核病，每周服用利福喷丁加异烟肼三个月。

背景：在印度计划条件下，对高危人群实施为期三个月的每周异烟肼（H，INH）和利福喷汀（P，RPT）（3HP）结核病预防疗法（TPT）的证据有限：方法：开展了一项前瞻性示范研究，评估 3HP TPT 在印度计划环境中艾滋病毒感染者（PLHIV）中的推广、安全性和有效性：在 656 名经过筛查的艾滋病毒感染者中，502 人（77%）接受了 3HP 治疗。其中，20 人（4%）因毒性中止了 TPT，17 人（3.8%）失去了随访，1 人（0.2%）出现了突破性利福平敏感结核病，464 人（92%）完成了 3HP TPT。在288例（57%）总体不良事件（AEs）中，46例（9%）为2级或2级以上不良事件。发生 AE 的中位时间为 14 天（IQR 7-42）。9名参与者（2%）报告了严重不良事件（SAE），其中7名（78%）与3HP无关。结论：3HP TPT 的完成率为 92%，导致停用 3HP 的不良事件很少，证明了 3HP TPT 在印度卫生项目环境中的 PLHIV 中的可扩展性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

IJTLD open

自引率

0.00%

发文量

期刊最新文献

Assessing the accuracy of the updated Fujifilm SILVAMP TB LAM II assay between lot numbers. Closing the gaps in childhood TB detection. Comparative efficacy of tetracyclines against isolates of Mycobacterium avium complex. Efficacy and safety data on pretomanid for drug-resistant TB. Ending the TB epidemic - what can we learn from the HIV epidemic?